成片一卡三卡四卡免费网站,色婷婷五月天,一日本道伊人久久综合影,XXXX张怕芝XXXXXBBBBB

English

ENDPOINTSNEWS: On a quest to challenge Novo Nordisk in obesity, transpacific startup picks up $70M — and a pair of seasoned execs

2021-10-13

新聞截圖.png

— AUTHOR: Amber Tong, Senior Editor

— REPRINTED FROM ENDPOINTSNEWS

— ORIGINAL LINK: https://endpts.com/on-a-quest-to-challenge-novo-nordisk-in-obesity-transpacific-startup-picks-up-70m-and-a-pair-of-seasoned-execs/

Four years after starting Terns Pharmaceuticals together in search of an elusive NASH win, Weidong Zhong and Martijn Fenaux are reuniting at a new startup.

On paper, Sciwind Biosciences — which just raised $70 million in Series C cash — employs a similar setup as Terns: Both have embraced the transpacific model, taking root in China but planting flags in the US.

Zhong was tapped to be president of the San Francisco-based subsidiary back in July, on top of assuming the role as chief strategy officer. Weeks later, Fenaux has been appointed SVP, nonclinical development and translational science at the parent company out of Hangzhou — joining the team alongside chief scientific officer Xinle Wu, who brings experience running R&D for both Eli Lilly and Amgen in China.

Whereas Terns is focused on NASH and other liver diseases, Sciwind positions itself as a specialist in metabolic disorders. The three lead candidates all congregate around GLP-1 receptor agonism, a mechanism that Sciwind reckons is relevant across fatty liver, obesity and diabetes.

The new infusion marks Sciwind’s second financing in a year, having bagged $37 million in February to fuel the clinical work underway for XW003 (long-acting GLP-1 peptide analog) in type 2 diabetes and obesity. Topline Phase II data are expected in the second half of 2022.

To reach those massive markets, the biotech would first have to steer past giant rivals like Novo Nordisk, whose GLP-1 peptide analog semaglutide is already approved in the US for both of those indications.

Then there's the follow-on XW004, which is designed for once daily rather than once weekly administration, slated for first-in-human trials later this year; and XW014, a preclinical small molecule GLP-1R agonist.

But IDG Capital, Loyal Valley Capital and LYFE Capital have no trouble believing in Sciwind and founder/CEO Hai Pan, leading the latest round.

熟女乱伦亚洲色图 | 99riva久久婷 | 国产亚洲精品久久久久久豆腐 | 17.c蜜桃视频红桃视频 | 国产又黄又爽在线 | 欧美一夜爽爽爽爽爽爽爽 | 国产一区在线午夜福利影片观看 | 少妇大叫太大太粗太爽了A片软件 | 免费无码高潮又爽又刺激 | 亚洲精品一区久久久久久 | 四川少妇BBBBBB爽爽小说 | 亚洲精品无码视频在线观看 | 视频1区视频2区 | 国产精品高清网站 | 欧美精品乱码久久久久蜜桃 | 中文字幕高清免费aV片 | 撸 换妻 浪女 一区 精品乱码一区内射人妻 | 成人做爰A片免费看黄冈 | 中文字幕丰满子伦无码专区 | 久久久久亚洲AV无码专区首jn | 无码人妻熟妇aV又粗又大 | 欧美色图日韩专区 | 少妇把腿扒开让我添6912p | 偷窥自拍亚洲色图 | 亚洲AV无码乱码棈品熟妇 | 免费看无码网站成人A片 | 少妇久久久一品二品 | 国产农村妇女精品一二三区 | |久久精品|69av | 亚洲国产精品无码成人片久久 | 国产69tv精品久久久久视频 | 精品国产免费一区二区三区香蕉 | gogo久久精品日本无码 | 无码人妻一区二区三区线花季转件 | 欧美一交一乱一交免费看 | XXXX性bbbb| 精品亚洲Aⅴ无码一区二区三区 | 97伦伦午夜电影理伦片 | 女主播深夜激情在线观看 | 国产精品h视频成人 | 国产激情综合五月久久 |